BACKGROUND:Bortezomib is active for newly diagnosed and relapsed multiple myeloma, and it has synergistic activity with melphalan. The authors of this report conducted a randomized trial to determine the safety and efficacy of adding bortezomib to a preparative regimen of arsenic trioxide (ATO), ascorbic acid (AA), and melphalan. METHODS: Among 60 patients who enrolled between October 2006 and September 2007, 58 patients underwent autologous transplantation with a preparative regimen ofmelphalan 200 mg/m(2) intravenously, AA 1000 mg daily intravenously for 7 days, and ATO 0.25 mg/kg intravenously for 7 days. Patients were randomized to receive no bortezomib (Group 1), bortezomib 1 mg/m(2) × 3 doses (Group 2), and bortezomib 1.5 mg/m(2) × 3 doses (Group 3). Primary endpoints were complete response (CR), grade IV toxicity, and 90-day treatment-related mortality (TRM). Secondary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: The median follow-up of all surviving patients was 36 months (range, 20-43 months). The CR rates in Groups 1, 2, and 3 were 20%, 10%, and 10%, respectively. Grade 3 and 4 nonhematologic toxicities and TRM were comparable. The median OS was not reached in the groups, whereas the median PFS in Groups 1, 2, and 3 was 17.8 months, 17.4 months, and 20.7 months, respectively. PFS and OS were significantly shorter in patients who had high-risk cytogenetics (P = .016 and P = .0001, respectively) and relapsed disease (P = .0001 and P = .0001, respectively) regardless of the treatment group. CONCLUSIONS: Adding bortezomib to a preparative regimen of ATO, AA, and high-dose melphalan was safe and well tolerated in patients with multiple myeloma. There was no significant improvement in the CR rate, PFS, or OS in the bortezomib groups.
RCT Entities:
BACKGROUND:Bortezomib is active for newly diagnosed and relapsed multiple myeloma, and it has synergistic activity with melphalan. The authors of this report conducted a randomized trial to determine the safety and efficacy of adding bortezomib to a preparative regimen of arsenic trioxide (ATO), ascorbic acid (AA), and melphalan. METHODS: Among 60 patients who enrolled between October 2006 and September 2007, 58 patients underwent autologous transplantation with a preparative regimen of melphalan 200 mg/m(2) intravenously, AA 1000 mg daily intravenously for 7 days, and ATO 0.25 mg/kg intravenously for 7 days. Patients were randomized to receive no bortezomib (Group 1), bortezomib 1 mg/m(2) × 3 doses (Group 2), and bortezomib 1.5 mg/m(2) × 3 doses (Group 3). Primary endpoints were complete response (CR), grade IV toxicity, and 90-day treatment-related mortality (TRM). Secondary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: The median follow-up of all surviving patients was 36 months (range, 20-43 months). The CR rates in Groups 1, 2, and 3 were 20%, 10%, and 10%, respectively. Grade 3 and 4 nonhematologic toxicities and TRM were comparable. The median OS was not reached in the groups, whereas the median PFS in Groups 1, 2, and 3 was 17.8 months, 17.4 months, and 20.7 months, respectively. PFS and OS were significantly shorter in patients who had high-risk cytogenetics (P = .016 and P = .0001, respectively) and relapsed disease (P = .0001 and P = .0001, respectively) regardless of the treatment group. CONCLUSIONS: Adding bortezomib to a preparative regimen of ATO, AA, and high-dose melphalan was safe and well tolerated in patients with multiple myeloma. There was no significant improvement in the CR rate, PFS, or OS in the bortezomib groups.
Authors: Nicholas Mitsiades; Constantine S Mitsiades; Paul G Richardson; Vassiliki Poulaki; Yu-Tzu Tai; Dharminder Chauhan; Galinos Fanourakis; Xuesong Gu; Charles Bailey; Marie Joseph; Towia A Libermann; Robert Schlossman; Nikhil C Munshi; Teru Hideshima; Kenneth C Anderson Journal: Blood Date: 2002-11-07 Impact factor: 22.113
Authors: Nikhil C Munshi; Kenneth C Anderson; P Leif Bergsagel; John Shaughnessy; Antonio Palumbo; Brian Durie; Rafael Fonseca; A Keith Stewart; Jean-Luc Harousseau; Meletios Dimopoulos; Sundar Jagannath; Roman Hajek; Orhan Sezer; Robert Kyle; Pieter Sonneveld; Michele Cavo; S Vincent Rajkumar; Jesus San Miguel; John Crowley; Hervé Avet-Loiseau Journal: Blood Date: 2011-02-03 Impact factor: 22.113
Authors: J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby Journal: N Engl J Med Date: 2003-05-08 Impact factor: 91.245
Authors: Athanasios Anagnostopoulos; Ana Aleman; Gregory Ayers; Michele Donato; Richard Champlin; Donna Weber; Raymond Alexanian; Sergio Giralt Journal: Cancer Date: 2004-06-15 Impact factor: 6.860
Authors: Paul G Richardson; Bart Barlogie; James Berenson; Seema Singhal; Sundar Jagannath; David Irwin; S Vincent Rajkumar; Gordan Srkalovic; Melissa Alsina; Raymond Alexanian; David Siegel; Robert Z Orlowski; David Kuter; Steven A Limentani; Stephanie Lee; Teru Hideshima; Dixie-Lee Esseltine; Michael Kauffman; Julian Adams; David P Schenkein; Kenneth C Anderson Journal: N Engl J Med Date: 2003-06-26 Impact factor: 91.245
Authors: Mark H Ma; Hank H Yang; Kimberly Parker; Steven Manyak; Jeffrey M Friedman; Cibby Altamirano; Zhi-qun Wu; Mitesh J Borad; Malka Frantzen; Evanthia Roussos; Jason Neeser; Amy Mikail; Julian Adams; Nelida Sjak-Shie; Robert A Vescio; James R Berenson Journal: Clin Cancer Res Date: 2003-03 Impact factor: 12.531
Authors: Danka Cholujova; Zdenka Bujnakova; Erika Dutkova; Teru Hideshima; Richard W Groen; Constantine S Mitsiades; Paul G Richardson; David M Dorfman; Peter Balaz; Kenneth C Anderson; Jana Jakubikova Journal: Br J Haematol Date: 2017-10-19 Impact factor: 6.998
Authors: Ulas D Bayraktar; Qaiser Bashir; Muzaffar Qazilbash; Richard E Champlin; Stefan O Ciurea Journal: Biol Blood Marrow Transplant Date: 2012-08-24 Impact factor: 5.742
Authors: Koji Sasaki; Gary Lu; Rima M Saliba; Qaiser Bashir; Chitra Hosing; Uday Popat; Nina Shah; Simrit Parmar; Yvonne Dinh; Sairah Ahmed; Elizabeth J Shpall; Partow Kebriaei; Jatin J Shah; Robert Z Orlowski; Richard Champlin; Muzaffar H Qazilbash Journal: Biol Blood Marrow Transplant Date: 2013-05-31 Impact factor: 5.742
Authors: M Valenzuela; C Glorieux; J Stockis; B Sid; J M Sandoval; K B Felipe; M R Kviecinski; J Verrax; P Buc Calderon Journal: Br J Cancer Date: 2014-07-08 Impact factor: 7.640